Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 31 citing articles:

Breakthroughs in Hepatocellular Carcinoma Therapies
Amit G. Singal, Masatoshi Kudo, Jordi Bruix
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 8, pp. 2135-2149
Open Access | Times Cited: 81
Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study
Masatoshi Kudo, Tomoko Aoki, Kazuomi Ueshima, et al.
Liver Cancer (2023) Vol. 12, Iss. 4, pp. 321-338
Open Access | Times Cited: 68
Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy
Takeshi Hatanaka, Yutaka Yata, Atsushi Naganuma, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1798-1798
Open Access | Times Cited: 28
Safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria
Lixing Li, Xin Xu, Wentao Wang, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e010035-e010035
Open Access | Times Cited: 1
A Prospective, Single-Arm, Phase 2 Study of Modified Transarterial Chemoembolization Using Low-Dose Chemotherapy with Blank Microspheres Plus Low-Dose Lenvatinib and Microwave Ablation in Patients with Large (≥7 cm) Unresectable Hepatocellular Carcinoma: The TALEM Trial
Zhimei Huang, Xue Han, Jian Wang, et al.
Liver Cancer (2024) Vol. 13, Iss. 4, pp. 438-450
Open Access | Times Cited: 4
Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapy-based systemic therapy
Bernhard Scheiner, Beodeul KANG, Lorenz Balcar, et al.
Hepatology (2024)
Closed Access | Times Cited: 4
Targeting JAML promotes normalization of tumour blood vessels to antagonize tumour progression via FAK/SRC and VEGF/VEGFR2 signalling pathways
Yanan Liu, Yawen Zheng, Xinchao Zhao, et al.
Life Sciences (2025) Vol. 368, pp. 123474-123474
Closed Access
Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma
Yoshihisa Kodama, Kazuomi Ueshima, Michihisa Moriguchi, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Efficacy and safety of radiotherapy versus transarterial chemoembolization in combination with lenvatinib and camrelizumab for hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: a multicenter study
Qizhen Huang, Xiaohong Zhong, Shaoxing Chen, et al.
Hepatology International (2025)
Closed Access
Harnessing nanoparticles for reshaping tumor immune microenvironment of hepatocellular carcinoma
Jinsong Li, GuanBo Zhang, Gang Li, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Dose-response relationships in Y90 resin microsphere radioembolization for patients with hepatocellular carcinoma: insights from a Brazilian cohort
Marcela Juliano Silva Cunha, Francisco Leonardo Galastri, Felipe Nasser, et al.
Einstein (São Paulo) (2025) Vol. 23
Open Access
Calceolarioside B targets MMP12 in the tumor microenvironment to inhibit M2 macrophage polarization and suppress hepatocellular carcinoma progression
Linna Cao, Miaomiao Shao, Yifei Gu, et al.
Phytomedicine (2025), pp. 156805-156805
Closed Access
Predictive Factors of Complete Response to Transarterial Chemoembolization in Intermediate Stage Hepatocellular Carcinoma beyond Up-To-7 Criteria
Natsuhiko Saito, Hideyuki Nishiofuku, Takeshi Sato, et al.
Cancers (2023) Vol. 15, Iss. 9, pp. 2609-2609
Open Access | Times Cited: 8
Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma
Valentina Zanuso, Angelo Pirozzi, Rita Balsano, et al.
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 1689-1708
Open Access | Times Cited: 7
Roles and Mechanisms of Ferroptosis in Sorafenib Resistance for Hepatocellular Carcinoma
Ruyuan Liu, Huanyu Cui, Di Li, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 2493-2504
Open Access | Times Cited: 2
All Stages of Hepatocellular Carcinoma Patients Benefit from Systemic Therapy Combined with Locoregional Therapy
Masatoshi Kudo
Liver Cancer (2023) Vol. 12, Iss. 5, pp. 395-404
Open Access | Times Cited: 6
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate‐stage hepatocellular carcinoma
Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Liver International (2023) Vol. 44, Iss. 1, pp. 113-124
Open Access | Times Cited: 6
Current Therapeutic Strategies for Hepatocellular Carcinoma in Japan
Masatoshi Kudo
Liver Cancer (2023) Vol. 12, Iss. 6, pp. 497-509
Open Access | Times Cited: 6
The rapidly evolving landscape of HCC: Selecting the optimal systemic therapy
Valentina Zanuso, Lorenza Rimassa, Chiara Braconi
Hepatology (2023)
Closed Access | Times Cited: 4
Nivolumab as Second-Line Therapy Improves Survival in Patients with Unresectable Hepatocellular Carcinoma
Faisal M. Sanai, Hassan Odah, Kanan Alshammari, et al.
Cancers (2024) Vol. 16, Iss. 12, pp. 2196-2196
Open Access | Times Cited: 1
Machine Perfusion as a Strategy to Decrease Ischemia-Reperfusion Injury and Lower Cancer Recurrence Following Liver Transplantation
Karla Bracho Garcia, Ahmed Hussein, Sangeeta Satish, et al.
Cancers (2024) Vol. 16, Iss. 23, pp. 3959-3959
Open Access | Times Cited: 1
Sintilimab plus bevacizumab followed by resection in intermediate-stage hepatocellular carcinoma: a phase Ib clinical trial with biomarker analysis
Hui‐Chuan Sun, Xiao‐Dong Zhu, Ziyi Wang, et al.
BMJ Oncology (2024) Vol. 3, Iss. 1, pp. e000578-e000578
Open Access | Times Cited: 1
The Extended Surgical Concepts for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors
Hsiao-Mei Hsu, Hsin‐I Tsai, Wei‐Chen Lee, et al.
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 1873-1880
Open Access | Times Cited: 3
Does autoimmune disease impair the survival of hepatocellular carcinoma patients undergoing liver resection? A multi-institutional observational study
Chao‐Wei Lee, Hsing‐Yu Chen, Ping‐Han Tsai, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 7
Open Access
Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study
Xiao Shen, Jin-Xing Zhang, Jin Liu, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 1993-2003
Open Access
Page 1 - Next Page

Scroll to top